Hidradenitis suppurativa – biologic therapy and other available treatment options

New and Emerging Targeted Therapies for Hidradenitis Suppurativa

“…The registration of a new biologic drug requires evidence for effectiveness and safety in randomized controlled trials [ 191 ]. However, the inclusion criteria for randomized clinical studies have mostly included patients with scarring components (which excludes mild disease), and the exclusion criteria were often applied to patients who need the most demanding therapy (Hurley III) [ 191 ]. Therefore, this can cover up the true effectiveness of the drug.…”

Closed‐loop systems in Type 1 diabetes and antitumor necrosis factor alpha therapy: Are currently available algorithms prepared for sudden changes in insulin sensitivity?

“…Cell immunity and proinflammatory cytokines including TNF‐α are involved in the pathogenic process of HS. 2 , 3 Data on sex hormones suggest that androgen excess may favor HS development in female patients. In conceptual agreement, the presence of functional hyperandrogenism in one out of every four female patients with T1D may underline the high frequency of newly diagnosed HS among these women.…”

“…None of the authors have any competing financial interest to disclose. Lía Nattero-Ch avez 1,2,3 Jorge Bondía 3,4 Héctor F. Escobar-Morreale 1,2,3 Manuel Luque-Ramírez…”

Misfortunes never come singly but in fours – follicular occlusion tetrad

“…In recent years, promising results in the treatment of hidradenitis suppurativa have been achieved through research on biologic drugs. The best-studied drug is adalimumab, but in single case reports, improvement in the course of hidradenitis suppurativa has been shown for infliximab, secukinumab, certolizumab, tildrakizumab, ixekizumab, and brodalumab [ 18 ].…”